MINNEAPOLIS, January 14, 2021 / PRNewswire / – Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a.m. CST review the financial results for the second quarter of 2021.
Access to the discussion can be obtained as follows:
A recorded replay will be available to interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referring to the Conference ID 13715028.
The replay will be available from 11:00 a.m. CST on Tuesday, February 2, 2021 until 11:00 p.m. CST Tuesday, March 2, 2021.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins and reactive solutions, including cytokines and growth factors, antibodies, immunoassays, biologically small molecule compounds active agents, tissue culture reagents and T cell activation technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand, providing researchers with efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products, including FDA regulated controls, calibrators, blood gas and clinical chemistry controls, and the development of custom tests on dedicated clinical instruments. Bio-Techne’s genomics tools include advanced tissue-based in situ hybridization (ISH) assays for research and clinical use, sold under the ACD brand as well as a portfolio of molecular diagnostic oncology assays clinical, including ExoDx®Prostate (IntelliScore) (PPE) for the diagnosis of prostate cancer. These diagnostic and genomics products constitute the Diagnostic and Genomics Branch of Bio-Techne. Bio-Techne products are an integral part of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They contribute to drug discovery efforts and provide the means to perform accurate clinical tests and diagnostics. With thousands of products in its portfolio, Bio-Techne has generated approximately $ 739 million of net sales in fiscal year 2020 and has approximately 2,300 employees worldwide.
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-february-2-2021-to-announce-second-quarter-2021-financial-results-301208162. html
SOURCE Bio-Techne Corporation